Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature
Erlotinib is currently marketed at fixed standard dosage against pancreatic cancer and non–
small-cell lung carcinoma. However, erlotinib pharmacokinetics (PK) is characterized by …
small-cell lung carcinoma. However, erlotinib pharmacokinetics (PK) is characterized by …
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)
M Hidalgo, D Bloedow - Seminars in oncology, 2003 - Elsevier
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model
A Gruber, M Czejka, P Buchner, M Kitzmueller… - Cancer chemotherapy …, 2018 - Springer
Purpose In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer
patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma …
patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma …
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer
JF Lu, SM Eppler, J Wolf, M Hamilton… - Clinical …, 2006 - Wiley Online Library
Objective Our objective was to assess the pharmacokinetics of erlotinib in a large patient
population with solid tumors, identify covariates, and explore relationships between …
population with solid tumors, identify covariates, and explore relationships between …
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of …
M Ranson, H Shaw, J Wolf, M Hamilton… - Cancer chemotherapy …, 2010 - Springer
Purpose An intravenous (IV) erlotinib formulation has not been characterized in cancer
patients but may be useful in those with gastrointestinal abnormalities that impact on the …
patients but may be useful in those with gastrointestinal abnormalities that impact on the …
Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?
GN Hortobagyi, G Sauter - Seminars in oncology, 2003 - Elsevier
The development of targeted agents has brought new opportunities and extraordinary
therapeutic challenges to cancer therapy. Several agents that inhibit epidermal growth factor …
therapeutic challenges to cancer therapy. Several agents that inhibit epidermal growth factor …
Preclinical studies with erlotinib (Tarceva)
RW Akita, MX Sliwkowski - Seminars in oncology, 2003 - Elsevier
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
Erlotinib Hydrochloride
LA Sorbera, J Castaner, JS Silvestre… - Drugs of the Future, 2002 - access.portico.org
The epidermal growth factor receptor (EGFR) is a type 1 receptor tyrosine kinase that is
involved in the modulation of cellular differentiation and is overexpressed in many types of …
involved in the modulation of cellular differentiation and is overexpressed in many types of …
Serum concentration of erlotinib and its correlation with outcome and toxicity in patients with advanced-stage NSCLC
O Fiala, P Hosek, M Pesek, J Finek, J Racek… - Anticancer …, 2017 - ar.iiarjournals.org
Background: Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor
receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer …
receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer …
[HTML][HTML] Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay
Y Yamamoto, T Saita, Y Yamamoto, M Shin - Journal of Pharmaceutical …, 2018 - Elsevier
A selective and sensitive competitive enzyme-linked immunosorbent assay (ELISA) method
was developed and validated for the quantification of erlotinib in 50 µL of samples of human …
was developed and validated for the quantification of erlotinib in 50 µL of samples of human …